297 related articles for article (PubMed ID: 19671679)
1. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.
Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
J Thorac Oncol; 2011 Jan; 6(1):15-20. PubMed ID: 21150464
[TBL] [Abstract][Full Text] [Related]
4. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
6. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
Shibata T; Hanada S; Kokubu A; Matsuno Y; Asamura H; Ohta T; Sakamoto M; Hirohashi S
Cancer Sci; 2007 Jul; 98(7):985-91. PubMed ID: 17459062
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
[TBL] [Abstract][Full Text] [Related]
9. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
11. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.
Wagner PL; Stiedl AC; Wilbertz T; Petersen K; Scheble V; Menon R; Reischl M; Mikut R; Rubin MA; Fend F; Moch H; Soltermann A; Weder W; Altorki NK; Perner S
Lung Cancer; 2011 Oct; 74(1):118-23. PubMed ID: 21477882
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations in non-small cell lung cancer.
Riely GJ; Marks J; Pao W
Proc Am Thorac Soc; 2009 Apr; 6(2):201-5. PubMed ID: 19349489
[TBL] [Abstract][Full Text] [Related]
13. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations.
Jeuken J; van den Broecke C; Gijsen S; Boots-Sprenger S; Wesseling P
Acta Neuropathol; 2007 Aug; 114(2):121-33. PubMed ID: 17588166
[TBL] [Abstract][Full Text] [Related]
14. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.
Wagner PL; Perner S; Rickman DS; LaFargue CJ; Kitabayashi N; Johnstone SF; Weir BA; Meyerson M; Altorki NK; Rubin MA
Am J Clin Pathol; 2009 Oct; 132(4):500-5. PubMed ID: 19762526
[TBL] [Abstract][Full Text] [Related]
15. Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.
Kowalczuk O; Kozlowski M; Milewski R; Minarowski L; Reszec J
Adv Med Sci; 2015 Sep; 60(2):277-86. PubMed ID: 26118982
[TBL] [Abstract][Full Text] [Related]
16. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
17. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.
Zhang S; Xia B; Jiang H; Wang L; Xu R; Shi Y; Zhang J; Xu M; Cram DS; Ma S
Oncotarget; 2016 Aug; 7(31):50477-50489. PubMed ID: 27409166
[TBL] [Abstract][Full Text] [Related]
19. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
20. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
Vandal G; Geiling B; Dankort D
PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
